S&P 500   3,971.27 (-0.16%)
DOW   32,394.25 (-0.12%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
S&P 500   3,971.27 (-0.16%)
DOW   32,394.25 (-0.12%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
S&P 500   3,971.27 (-0.16%)
DOW   32,394.25 (-0.12%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
S&P 500   3,971.27 (-0.16%)
DOW   32,394.25 (-0.12%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
NASDAQ:TOI

Oncology Institute - TOI Stock Forecast, Price & News

$0.66
-0.07 (-10.13%)
(As of 03/28/2023 05:23 PM ET)
Add
Compare
Today's Range
$0.62
$0.73
50-Day Range
$0.48
$1.65
52-Week Range
$0.46
$10.26
Volume
106,506 shs
Average Volume
167,834 shs
Market Capitalization
$49.17 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.50

Oncology Institute MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
884.8% Upside
$6.50 Price Target
Short Interest
Bearish
3.48% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.18mentions of Oncology Institute in the last 14 days
Based on 5 Articles This Week
Insider Trading
Acquiring Shares
$27,500 Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.31 out of 5 stars

Medical Sector

280th out of 1,002 stocks

Offices & Clinics Of Medical Doctors Industry

2nd out of 7 stocks


TOI stock logo

About Oncology Institute (NASDAQ:TOI) Stock

The Oncology Institute, Inc., an oncology company, provides medical oncology services in the United States. Its services include physician services, in-house infusion and dispensary, clinical trial services, radiation, outpatient stem cell transplants and transfusions programs, and patient support. The company also offers and manages clinical trial services, such as managing clinical trials, palliative care programs, and stem cell transplants services. It serves adult and senior cancer patients. The company operates 67 clinic locations. The Oncology Institute, Inc. was founded in 2007 and is based in Cerritos, California.

Receive TOI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oncology Institute and its competitors with MarketBeat's FREE daily newsletter.

TOI Stock News Headlines

A strange force is brewing…
An economic force with the potential to be bigger than the 1880s railroad boom, the 1920s automobile boom, the baby boom of the 1960s, or the Dotcom boom of the ‘90s. And while Biden has nothing to do with it… he’ll take full credit. pixel
Oncology Institute (NASDAQ:TOI) Price Target Cut to $3.00
A strange force is brewing…
An economic force with the potential to be bigger than the 1880s railroad boom, the 1920s automobile boom, the baby boom of the 1960s, or the Dotcom boom of the ‘90s. And while Biden has nothing to do with it… he’ll take full credit. pixel
Q4 2022 Oncology Institute Inc Earnings Call
SA lands millions in new state cancer research funding
The Oncology Institute, Inc. (TOI)
Precision Oncology – the new way forward
TOI The Oncology Institute, Inc.
The Oncology Institute Expands Into Chino, CA
The Oncology Institute Rebrands Clinical Trials Division
See More Headlines
Receive TOI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oncology Institute and its competitors with MarketBeat's FREE daily newsletter.

TOI Company Calendar

Today
3/28/2023
Next Earnings (Estimated)
5/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Offices & clinics of medical doctors
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TOI
Fax
N/A
Employees
658
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.50
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+885.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$150,000.00
Pretax Margin
-0.04%

Debt

Sales & Book Value

Annual Sales
$252.48 million
Cash Flow
$0.01 per share
Book Value
$1.68 per share

Miscellaneous

Free Float
66,799,000
Market Cap
$49.17 million
Optionable
Not Optionable
Beta
1.01

Key Executives

  • Mr. Richard Alan Barasch (Age 68)
    Exec. Chairman
  • Mr. Bradford D. Hively
    CEO & Director
  • Dr. Daniel Virnich FACHE (Age 43)
    M.B.A., M.D., MBA, Pres
    Comp: $297.6k
  • Ms. Hilda Agajanian M.B.A.
    Founder & Chief Growth Officer
  • Dr. Richy Agajanian M.D.
    Founder & Chief Clinical Officer
  • Mr. Mihir Arunkumar Shah CPA (Age 44)
    Chief Financial Officer
  • Dr. Matthew Miller M.B.A. (Age 45)
    M.D., Chief Operating Officer
  • Mr. Rakesh Singh M.B.A.
    Director of Technology
  • Mr. G. Philip Reger
    Chief Information Officer
  • Mr. Mark Hueppelsheuser Esq.
    Gen. Counsel













TOI Stock - Frequently Asked Questions

Should I buy or sell Oncology Institute stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Oncology Institute in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TOI shares.
View TOI analyst ratings
or view top-rated stocks.

What is Oncology Institute's stock price forecast for 2023?

2 Wall Street analysts have issued 12 month price targets for Oncology Institute's shares. Their TOI share price forecasts range from $3.00 to $10.00. On average, they expect the company's share price to reach $6.50 in the next twelve months. This suggests a possible upside of 885.6% from the stock's current price.
View analysts price targets for TOI
or view top-rated stocks among Wall Street analysts.

How have TOI shares performed in 2023?

Oncology Institute's stock was trading at $1.65 at the start of the year. Since then, TOI stock has decreased by 60.0% and is now trading at $0.6595.
View the best growth stocks for 2023 here
.

When is Oncology Institute's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 10th 2023.
View our TOI earnings forecast
.

What guidance has Oncology Institute issued on next quarter's earnings?

Oncology Institute issued an update on its FY 2023 earnings guidance on Thursday, March, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $290.00 million-$320.00 million, compared to the consensus revenue estimate of $308.75 million.

What is Oncology Institute's stock symbol?

Oncology Institute trades on the NASDAQ under the ticker symbol "TOI."

Who are Oncology Institute's major shareholders?

Oncology Institute's stock is owned by many different institutional and retail investors. Top institutional investors include Geode Capital Management LLC (0.71%), Triatomic Management LP (0.70%), Jefferies Financial Group Inc. (0.26%), Josh Arnold Investment Consultant LLC (0.14%), Two Sigma Investments LP (0.07%) and Alpine Global Management LLC (0.06%). Insiders that own company stock include Havencrest Healthcare Partners, Matthew P Miller, Mohit Kaushal, Richard A Barasch and Richy Agajanian.
View institutional ownership trends
.

How do I buy shares of Oncology Institute?

Shares of TOI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Oncology Institute's stock price today?

One share of TOI stock can currently be purchased for approximately $0.66.

How much money does Oncology Institute make?

Oncology Institute (NASDAQ:TOI) has a market capitalization of $49.17 million and generates $252.48 million in revenue each year. The company earns $150,000.00 in net income (profit) each year or ($0.17) on an earnings per share basis.

How many employees does Oncology Institute have?

The company employs 658 workers across the globe.

How can I contact Oncology Institute?

Oncology Institute's mailing address is 345 PARK AVENUE SOUTH, NEW YORK NY, 10010. The official website for the company is theoncologyinstitute.com. The company can be reached via phone at 562-735-3226 or via email at investors@theoncologyinstitute.com.

This page (NASDAQ:TOI) was last updated on 3/28/2023 by MarketBeat.com Staff